RenovoRx Statistics
Total Valuation
RenovoRx has a market cap or net worth of $33.62 million. The enterprise value is $23.81 million.
Important Dates
The last earnings date was Thursday, November 13, 2025, after market close.
| Earnings Date | Nov 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
RenovoRx has 36.65 million shares outstanding. The number of shares has increased by 73.80% in one year.
| Current Share Class | 36.65M |
| Shares Outstanding | 36.65M |
| Shares Change (YoY) | +73.80% |
| Shares Change (QoQ) | +0.19% |
| Owned by Insiders (%) | 3.40% |
| Owned by Institutions (%) | 12.45% |
| Float | 32.79M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 32.08 |
| Forward PS | 8.94 |
| PB Ratio | 4.16 |
| P/TBV Ratio | 4.16 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 25.66 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.83, with a Debt / Equity ratio of 0.03.
| Current Ratio | 5.83 |
| Quick Ratio | 5.42 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -146.61% and return on invested capital (ROIC) is -94.41%.
| Return on Equity (ROE) | -146.61% |
| Return on Assets (ROA) | -68.39% |
| Return on Invested Capital (ROIC) | -94.41% |
| Return on Capital Employed (ROCE) | -124.65% |
| Revenue Per Employee | $92,800 |
| Profits Per Employee | -$1.11M |
| Employee Count | 10 |
| Asset Turnover | 0.09 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -27.19% in the last 52 weeks. The beta is 1.28, so RenovoRx's price volatility has been higher than the market average.
| Beta (5Y) | 1.28 |
| 52-Week Price Change | -27.19% |
| 50-Day Moving Average | 1.08 |
| 200-Day Moving Average | 1.11 |
| Relative Strength Index (RSI) | 47.77 |
| Average Volume (20 Days) | 375,296 |
Short Selling Information
The latest short interest is 676,264, so 1.85% of the outstanding shares have been sold short.
| Short Interest | 676,264 |
| Short Previous Month | 628,461 |
| Short % of Shares Out | 1.85% |
| Short % of Float | 2.06% |
| Short Ratio (days to cover) | 1.69 |
Income Statement
In the last 12 months, RenovoRx had revenue of $928,000 and -$11.11 million in losses. Loss per share was -$0.34.
| Revenue | 928,000 |
| Gross Profit | 629,000 |
| Operating Income | -11.62M |
| Pretax Income | -11.11M |
| Net Income | -11.11M |
| EBITDA | n/a |
| EBIT | -11.62M |
| Loss Per Share | -$0.34 |
Full Income StatementBalance Sheet
The company has $10.04 million in cash and $236,000 in debt, giving a net cash position of $9.81 million or $0.27 per share.
| Cash & Cash Equivalents | 10.04M |
| Total Debt | 236,000 |
| Net Cash | 9.81M |
| Net Cash Per Share | $0.27 |
| Equity (Book Value) | 8.08M |
| Book Value Per Share | 0.22 |
| Working Capital | 9.10M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$10.38 million and capital expenditures -$14,000, giving a free cash flow of -$10.40 million.
| Operating Cash Flow | -10.38M |
| Capital Expenditures | -14,000 |
| Free Cash Flow | -10.40M |
| FCF Per Share | -$0.28 |
Full Cash Flow StatementMargins
| Gross Margin | 67.78% |
| Operating Margin | -1,252.16% |
| Pretax Margin | -1,196.66% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
RenovoRx does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -73.80% |
| Shareholder Yield | -73.80% |
| Earnings Yield | -33.03% |
| FCF Yield | -30.92% |
Analyst Forecast
The average price target for RenovoRx is $7.75, which is 744.78% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $7.75 |
| Price Target Difference | 744.78% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 376.87% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
RenovoRx has an Altman Z-Score of -2.61 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.61 |
| Piotroski F-Score | 2 |
